After more than 2 years, the median duration of response was 12.4 months and no new safety signals were seen, according to Dr. Shirish Gadgeel, who presented the results during WCLC 2023. Read more

Dr. Solange Peters presented new follow-up data from CheckMate 227 that show positive results regardless of PD-L1 expression. Read more

During WCLC 2023, researcher Dr. Kevin Lamote shared data that demonstrated VOCs in exhaled breath could be a useful biomarker. Read more

IASLC leaders also shared highlights from the association’s membership growth and financial report and officially welcomed President Dr. Paul Van Schil. Read more

During the Presidential Plenary, investigator Dr. Eric Lim shared data comparing surgery plus chemotherapy to chemotherapy alone, one of several potentially practice-changing studies presented during the session. Read more

Data presented by patient advocate Jill Feldman and Nathan Harrison show that while the IASLC’s Language Guide is helping to reduce the use of stigmatizing language, research on the effects of stigma in lung cancer is lacking. Read more

Drs. Keith Kerr and Sanja Dacic will examine the role of pathology in patient selection and specimen interpretation in the era of neoadjuvant immunotherapy. Read more

Co-chair Dr. Pyng Lee said simply because a treatment has been approved does not make it an affordable and accessible clinical alternative for lung cancer patients in the real world. Read more

Drs. Claudia Henschke and Pan-Chy Yang to chair an education session designed to help thoracic oncologists translate research into successful lung cancer screening efforts. Read more

Drs. Hidehito Horinouchi and Stephen Liu will chair the session, which will explore multiple advances driving survival gains, including antibody-drug conjugates, bispecific T-cell engagers, and targeted therapies. Read more